Does ClearPath Diagnostics do in situ hybridization studies?
Yes. In situ hybridization is done on tissues to detect human papilloma virus and to determine the presence or absence of Her-2/neu gene amplification in breast cancer. In situ hybridization for detection of low and high risk human papilloma virus (HPV) is performed on formalin fixed, paraffin embedded tissue. The technique allows for specific nuclear localization of HPV DNA by light microscopy. In situ hybridization also is done for detection of Her-2/neu gene amplification. This technique utilizes fluorescence microscopy to determine the number of Her-2/neu genes in nuclei compared to the absolute chromosome 17 copy number. A ratio of greater than 2.0 indicates Her-2/neu amplification. ClearPath offers the following in situ hybridization studies: Human papilloma virus (HPV), Low RiskHuman papilloma virus (HPV), High RiskHer-2/neu (FISH).
